How are pharma and bio companies reshaping Korean skincare?

Drug developers are entering derma as a future cash cow, applying clinical R&D to barrier and regeneration claims — Dongkook's centella-based TECA line is one example [BioTimes 2025]. Amorepacific's Aestura barrier cream passed 10 m cumulative units and entered US Sephora [Metro Seoul 2025], while L'Oreal acquired Dr.G to deepen its Asian dermatological line [WWD 2025].

Why is Olive Young the key validation shelf for dermocosmetics?

Olive Young finished 2025 at KRW 5.83 trn, +21.8% [Olive Young AR 2025], and the legacy-major share of its premium shelf fell from ~70% in 2018 to below 45% by 2025 [PwC K-beauty 2025] — replaced by a long indie tail. The US generated more than half of its global sales in H1 2025 [Olive Young AR 2025].

How does Korean dermocosmetics perform on Amazon and US specialty retail?

Korean products are the fastest-scaling beauty segment on Amazon, growing ~3x the category average [Olive Young AR 2025]; on one 2025 count, 10 of the top 50 US Amazon skincare best-sellers were Korean [KOTRA 2025]. Anua passed USD 500 m in 2025 retail sales on a barrier-repair platform [WWD 2025].

0 2 4 6 0.5 4.5 5.5E 2017 2019 2021 2022 2025E

Chart: Domestic dermocosmetics market, South Korea · KRW trn · 2017–2025E. Source: Domestic derma-market reads, KIRA triangulation.

Methodology note: The domestic dermocosmetics series (KRW 0.5 trn in 2017 to ~KRW 4.5 trn in 2022, ~5.5 trn in 2025E) is a directional read triangulated from Korean-language industry reporting and brand disclosures [Kira estimates]; it is not an audited series. The ~13% category growth figure for 2024 is drawn from L'Oreal's dermocosmetics beauty-share estimate [L'Oreal 2024]. Anua's USD 500 m retail-sales claim is sourced from WWD 2025 brand reporting. Amazon best-seller share (10 of top 50) is sourced from KOTRA's US-market brief [KOTRA 2025].